Fundraising Fox
/Companies
Sign in

Curemark

Rye Brook, US · Delaware LLC · 1 known investors

Find your way into Curemark

Sign up to see every warm intro you have to Curemark

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Curemark team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Curemark is a clinical-stage biopharmaceutical company developing therapies for neuro-developmental and neurodegenerative disorders. Its lead candidate, CM-AT, is a disorder-modifying therapy for Autism.

BiotechHealthtech

Founders & leadership

JFJoan Fallon
Joan FallonFounder · CEOJoan Fallon is the founder and CEO of Curemark, a clinical-stage biopharmaceutical company developing therapies for neurodevelopmental and neurodegenerative disorders, with a lead program for autism. She holds over 300 patents, has lectured on pediatric developmental disorders, and serves as a senior advisor and fellow at academic institutions.
MHMatthew Heil
Matthew HeilChief Scientific Officer
KD
Kimball DuncanManager of the LLC
KK
Klaus KleinfeldManager of the LLC
EH
Eric HermanManager of the LLC

Board

LM
Leigh MorganBoard director
KD
Kimbell DuncanBoard director

Investors · 1

Funding

SEC filings, press & company announcements

$62.4M disclosed across 10 of 11 rounds · 2009–2023

▶$1.3MraisedMar 2023 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kimball DuncanDirector
  • Joan FallonExecutive Officer, Director
  • Leigh MorganDirector
  • Afia AsamoahDirector
  • Matthew HeilExecutive Officer
Offering amount
$15M
Amount sold
$1.3M
First sale
Jan 2023
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedApr 2021 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Leigh MorganDirector
  • Joan FallonExecutive Officer, Director
  • Matthew HeilExecutive Officer
  • Kimbell DuncanDirector
Offering amount
$5M
Amount sold
$1.5M
First sale
Mar 2021
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.4MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • KIMBELL DUNCANDirector
  • JENNIFER FRISTDirector
  • MATTHEW HEILExecutive Officer
  • JZANEEN LALANIExecutive Officer
  • JOAN FALLONExecutive Officer, Director
Offering amount
$50M
Amount sold
$5.4M
First sale
Aug 2019
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jzaneen LalaniExecutive Officer
  • Eric HermannDirector
  • Jennifer FristDirector
  • Matthew HeilExecutive Officer
  • Justin StebbingDirector
  • Joan FallonExecutive Officer, Director
Offering amount
$3M
Amount sold
$1.7M
Minimum investment
$1M
First sale
Apr 2018
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedJan 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric HermannDirector
  • Jennifer FristDirector
  • Jzaneen LalaniExecutive Officer
  • Matthew HeilExecutive Officer
  • Joan FallonExecutive Officer, Director
  • Justin StebbingDirector
Offering amount
$80M
Amount sold
$3.2M
First sale
Jan 2018
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedMar 2017 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew HeilExecutive Officer
  • Joan FallonExecutive Officer, Director
  • Eric HermannDirector
  • Jzaneen LalaniExecutive Officer
  • Justin StebbingDirector
  • Jennifer FristDirector
Offering amount
$150M
Amount sold
$3M
First sale
Mar 2017
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.3MraisedJul 2015 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew HeilExecutive Officer
  • Kimball DuncanDirector
  • Eric HermanDirector
  • Joan FallonExecutive Officer, Director
Offering amount
$29.5M
Amount sold
$20.3M
Proceeds to insiders
$800K
First sale
Jun 2015
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kimball DuncanDirector
  • Klaus KleinfeldDirector
  • Eric HermanDirector
  • Matthew HeilExecutive Officer
  • Joan FallonExecutive Officer, Director
Offering amount
$17.5M
Amount sold
$5M
Minimum investment
$1M
Proceeds to insiders
$1.6M
First sale
Dec 2014
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

CUREMARK Honored by Goldman Sachs for Entrepreneurshipprnewswire.com · Oct 2020CureMark Closes $6.5M Series A Financing - BioSpacebiospace.com · Aug 2009

Frequently asked questions

What does Curemark do?
Curemark is a clinical-stage biopharmaceutical company developing therapies for neuro-developmental and neurodegenerative disorders. Its lead candidate, CM-AT, is a disorder-modifying therapy for Autism.
Who founded Curemark?
Curemark was founded by Joan Fallon.
Who are Curemark's investors?
Curemark's investors include Social Impact Capital.
How much funding has Curemark raised?
Curemark has disclosed $62.4M raised across 10 of its 11 known rounds.
Where is Curemark headquartered?
Curemark is headquartered in Rye Brook, US.